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Abstract
Prostate cancer preferentially metastasizes to bone, which is rich in structural and matricellular proteins capable of
altering prostate cancer progression. This study explores the role of the bone stromal matricellular protein SPARC
(osteonectin/BM-40) in the progression of bone metastatic prostate cancer. Quantification of bone destruction
analyzed by micro–computed tomography showed augmented osteoclastic resorption, characterized by de-
creases in several morphometric bone parameters in SPARC knock out (KO) tibiae harboring RM1 murine prostate
cancer cells compared with wild type (WT) animals. Tumor progression stimulated osteoclast formation, which was
augmented in SPARC KO mice. In vitro differentiation of SPARC KO osteoclasts indicated accelerated progenitor ex-
pansion and formation of tartrate-resistant acid phosphatase–positive osteoclast-like cells with increased resorptive
capacity, a mechanism resulting in enhanced tumor-induced bone loss in vivo. Whereas altered bone structure due to
SPARC KO played a role in increased osteolysis, the enhanced osteolysis was primarily the result of increased re-
sorption by SPARC KO osteoclasts. Our findings indicate that bone stromal SPARC suppresses tumor-induced bone
lesion expansion by limiting osteoclast maturation and function.
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Introduction
Bone is a metastatic “hot spot” for several cancers including prostate
[1]. Prostate cancer has the highest incidence of all cancers in Western
males and accounts for 25% of reported cancers [2]. As bone metasta-
sis affects greater than 80% of patients with advanced prostate cancer
and determines patient morbidity and disease-related mortality, this
phase of prostate cancer deserves considerable attention. Previous stud-
ies using prostate cancer patient tissue samples reported that SPARC
(secreted protein acidic and rich in cysteine; osteonectin; BM-40) ex-
pression at metastatic sites is higher compared with that in primary
sites [3–5]. SPARC is a highly expressed matricellular protein in bone,
where its expression levels trail behind only that of collagens [6].
SPARC is of particular interest as it has been identified as a marker
of poor prognosis and aggressiveness in a large number of human can-
cers [7], although its role as a tumor initiator and stimulator of cancer
progression is not completely understood. In the case of prostate cancer,
SPARC has been shown to be predominantly protumorigenic [3,4,8].
Two animal model studies have investigated the role of SPARC in the
initiation and progression of prostate cancer, each by breeding SPARC
KOmice with TRAMP (transgenic adenocarcinoma of the mouse pros-
tate) mice. Wong et al., building on previous gene expression analyses
wherein it was determined that SPARC expression was decreased in
highly metastatic prostate cancer cells [9], found that heterozygous or
homozygous loss of SPARC expression in TRAMP mice had no effect
on the initiation or inhibition of prostate cancer [10]. Thus, this study
demonstrates that prostate cancer metastasis is unaltered by partial or
a complete absence of SPARC. In contrast, Said et al. [11], using a
separate homozygous SPARC KO/TRAMP model, reported SPARC
expression to be inhibitory for primary prostate cancer initiation and
progression. These findings illustrate the complexity of isolating a func-
tion for SPARC in primary prostate carcinogenesis, which may be
dependent on the level of SPARC expression or the background of
the mice tested. One additional limitation of the TRAMP prostate car-
cinogenesis model is a lack of bone metastases precluding the use of this
model for isolating a role of SPARC in prostate cancer bone metastasis.
We have previously demonstrated that prostate cancer cells migrate
toward bone extracts containing SPARC [12]. Exogenous SPARC
was also shown to act as a chemotactic factor by inducing prostate
cancer migration [8,13]. Thus, SPARC seems to be a promoter of
a promigratory and invasive phenotype of prostate cancer cells in vitro.
Conversely, several studies have reported the hypermethylation of
SPARC in prostate cancer tissues and in prostate cancer cells [9,14].
Therefore, a loss of endogenous SPARC expression by cancerous cells
results in their progression, and the levels of SPARC in the tumor and
stroma may differentially affect prostate cancer progression. Interestingly,
coculture of bone marrow and prostate cancer cells resulted in increased
SPARC expression and secretion [15]. Further, in an in vivo model of
prostate cancer growth in human bones implanted in mice, SPARC
expression was found in tumor cells, the bone matrix, and stromal cells
[15]. In addition, we have previously demonstrated that SPARC ex-
pression is increased in bone metastasis compared with the primary
tumor [12]. Thus, SPARC expression may have different functions at
primary and secondary tumor sites.
Nevertheless, it is unclear whether SPARC affects the development
of tumor-induced bone lesions and whether stromal SPARC affects
the expansion of bone lesions. In this study, we investigate the con-
sequences of SPARC deficiency within the tumor environment, but
not the tumor itself, on prostate cancer growth within the bone and
on bone lesion progression. For this purpose, we used SPARC-deficient
mice that received direct intraosseous injections of SPARC-expressing
syngeneic RM1 mouse prostate cancer cells. As such, we have used
a model wherein stromal SPARC expression is absent, while tumor
expression of SPARC remains. Our data illustrate an inhibitory role
for bone stromal SPARC in prostate cancer expansion in bone through
the regulation of osteoclast formation and function.
Materials and Methods
Mice and Cells
SPARC KO and SPARC WTmice of the same genetic background
(B6;129S) were a kind gift from Dr E.H. Sage and were backcrossed
to a C57BL/6 background for more than eight generations [16]. RM1
murine prostate cancer cells were provided by DrW. Heston (Cleveland
Clinic) and routinely cultured in RPMI 1640 supplemented with 10%
heat-inactivated FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin
with passage by trypsinization (0.05% trypsin, 0.53 mM EDTA). Cells
were used up to passage 12.
Intraosseous Implantations
Male 10- to 12-week-old SPARC KO or SPARC WT littermates
were anesthetized by intraperitoneal injection of 100 mg/kg ketamine
and 10 mg/kg xylazine. Intratibial injections have been described pre-
viously [17]. In brief, the knee area was prepared by shaving then scrub-
bing with a chlorhexidine solution. The knee was flexed, and a hole
was formed in the proximal end of the tibia using a 27-gauge needle.
A 29-gauge insulin needle/syringe was then inserted into this cortical
opening to deliver RM1 cells (1 × 103 cells) in suspension (PBS) to
the marrow space of the tibial metaphysis just distal to the growth plate.
The contralateral tibia was injected with PBS alone as a control (sham
injection). All animal procedures were performed in accordance with
an approved institutional protocol according to the guidelines of the
Institutional Animal Care and Use Committee of the Cleveland Clinic.
Micro–Computed Tomography Analysis
Micro–computed tomography (microCT) analysis of tibiae was per-
formed 1 day after cell implantation and after 14 days of tumor growth.
Scans were conducted in the Cleveland Clinic Biomedical Imaging
and Analysis Core Center on a GE eXplore Locus microCT (GE
Healthcare, Piscataway, NJ) and 360 X-ray projections were collected
in 1° increments (80 kV [peak], 500 mA, 26 minutes of total scan
time). Projection images were preprocessed and reconstructed into
three-dimensional volumes (10243 voxels, 20-μm resolution) on a
4PC reconstruction cluster using a modified tent-FDK cone-beam
algorithm (GE reconstruction software). Three-dimensional data were
processed and rendered (isosurface/maximum-intensity projections)
using MicroView (GE Healthcare). For each volume, a plane perpen-
dicular to the z-axis/tibial shaft was generated and placed at the base
of the growth plate. A second, parallel plane was defined 1.0 mm
below, and the entire volume was cropped to this volume of interest
for quantitative analysis. Image stacks from each volume of interest
were exported for quantitative analysis. Cancellous bone masks were
generated in MicroView, and three-dimensional trabecular structural
indices were extracted using custom MatLab (The MathWorks, Inc,
Natick, MA) algorithms. Trabecular thickness (Tb.Th) and trabecular
spacing (Tb.Sp) were determined by previously reported methods
[18]. Trabecular number (Tb.N) was calculated by taking the inverse
of the average distance between the medial axes of trabecular bone
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segments. Bone volume fraction (BV/TV, total bone voxels divided
by total cancellous bone mask voxels) and bone surface area (BSA,
sum of pixels along edges of trabecular bone) were also calculated for
each VOI.
Bone Histology
Fourteen days after cancer cell implantation, mice were sacrificed.
Bilateral tibiae, both tumor-bearing and contralateral control, were re-
moved and decalcified in EDTA during a 2-week period. Tibiae were
then processed for embedding in paraffin, and sections were cut for
staining with hematoxylin and eosin (H&E) to visualize tumors and
associated bone destruction. Separately, osteoclasts were stained for
tartrate-resistant acid phosphatase (TRAP) expression (0.1 mg/ml
naphthol AS-MX phosphate disodium salt, 0.01% [vol./vol.] Triton
X-100, 0.03 M sodium tartrate, 0.015 M acetic acid, 0.035 M sodium
acetate, and 0.3 mg/ml Fast Red Violet LB). Slides were counterstained
with Gill’s No. 3 hematoxylin solution. All chemicals were from Sigma-
Aldrich (St Louis, MO). Images were taken with a Leica DM2500
light microscope (Leica Microsystems, Bannockburn, IL).
Osteoclast Formation and Function
Tibiae and femurs were isolated from SPARC KO and SPARC WT
mice, and the bone ends were removed. Bone marrow (BM) was flushed
with PBS containing penicillin and streptomycin. Cell clumps were
dispersed by passing consecutively through 18-gauge and 21-gauge
needles. Isolated cells were plated (1 × 106) in α modified Eagle me-
dium (αMEM) containing 10% FBS, penicillin and streptomycin,
and 100 ng/ml murine macrophage colony-stimulating factor (M-CSF;
R&D Systems, Minneapolis, MN). After 3 days, adherent BM-derived
macrophages (BMMΦ) were stained with F4/80 Ab (AbD Serotec,
Raleigh, NC) followed by Alexa 488 (Life Technologies Corp, Carlsbad,
CA). 4′,6-Diamidino-2-phenylindole (DAPI) was used as a nuclear stain.
Cell counts and F4/80 positivity were determined using Image Pro soft-
ware (Media Cybernetics, Inc, Bethesda, MD). Separately, adherent
BMMΦs, grown in αMEM containing M-CSF (100 ng/ml) for 3 days,
were washed in cold PBS, and placed on ice for 30 minutes. Cells were
lifted and plated (5 × 105) inαMEMcontainingM-CSF (30 ng/ml) with
receptor activator of NF-κB ligand (RANKL; 100 ng/ml) on BDBioCoat
Osteologic Multitest slides (BD Biosciences, Bedford, MA) or Lab-Tek
Chamber slides (Nunc, Rochester, NY). Medium was replaced 2 days
after plating, and slides were examined 5 days after plating. Cells on
Osteologic slides were removed by incubating with bleach, washed,
and allowed to air dry. Cells in chamber slides were fixed in 10% glu-
taraldehyde for 15 minutes at 37°C then stained for TRAP expression.
Ten images per well were takenwith a lightmicroscope (DM2500; Leica
Microsystems). Image Pro software (Media Cybernetics) was used to
calculate total pit area and average pit area on Osteologic slides. Alter-
natively, the total number of TRAP-positive and cells containing more
than 3 nuclei (MNC; multinuclear cells) was counted.
Osteoclast Coculture
BM was isolated from the bones of SPARC WT and KO mice and
cultured in αMEM containing 100 ng/ml M-CSF for 3 days. The
resulting BMMΦs were either plated alone (1.8 × 104 cells/cm2) or
in coculture with RM1 cells (1:10; 1.6 × 104 cells/cm2 BMMΦs,
0.2 × 104 cells/cm2 RM1). In addition, RM1 cells were plated alone
(0.2 × 104 cells/cm2). Cultures were maintained in αMEM containing
100 ng/ml M-CSF in chamber slides and stained for TRAP expression
after 5 days.
Osteoclast Resorption of Parietal Bones
Parietal bones from SPARC KO and SPARC WTmice were har-
vested and then devitalized by placing bones in 70% ethanol and freez-
ing at −80°C. Bones were cut into a circle with a hole punch and placed
Figure 1. SPARC deficiency stimulates osteolysis. RM1 cells (1 × 103) were injected into the tibia of SPARCWT or KOmice. (A) Bones were
isolated after 2 weeks of intraosseous growth, sectioned, and stained with H&E. RM1 cells (T) can be seen growing in the proximal meta-
physis and have completely replaced the bone marrow. B indicates trabecular bone; GP, growth plate. Scale bars, 50 μm. (B) MicroCT-
derived transaxial slices from mice 1 day (initial) and 2 weeks (final) after tumor implantation. Severe osteolysis can be seen in KO mice.
Arrow indicates site of cortical breach. Representative images from nine mice are shown.
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in the wells of a 96-well plate containing PBS. After 1 hour in a cell
culture incubator at 37°C with 5% CO2, PBS was removed and
BMMΦ was isolated from SPARC KO or SPARCWTmice in αMEM
containing M-CSF (30 ng/ml) and RANKL (100 ng/ml) were added
to the wells. After 5 days, with medium replaced on day 3, bones were
removed and placed in bleach followed by a rinse in water. Bones were
visualized and photographed using a Leica DM2500 light microscope
at 10 different visual planes. The 10 images were compiled into a single
“optimal” image using Image Pro software. Pit areas were quantified
using National Institutes of Health ImageJ.
Statistical Analysis
Analysis of variance (one-way) followed by Tukey multiple com-
parison test or Student’s t test were used to calculate statistical signifi-
cance (GraphPad Prism 5.0, La Jolla, CA). Differences were considered
significant when P < .05. All data depicted and described in text are
mean ± SD. *P < .05, **P < .01, and ***P < .005.
Results
Stromal SPARC Suppresses Prostate
Cancer–Induced Osteolysis
Bones of SPARC KO mice were previously shown to contain re-
duced trabecular morphometric parameters and associated diminished
bone quality and strength as a result of reduced numbers of osteoblast
precursors and reduced osteoblast function owing to progressive low-
turnover osteopenia [19]. Our own morphometric values determined
bymicroCT confirmed reduced trabecular numbers and morphometric
parameters (Figure W1). Using SPARC- and RANKL-expressing RM1
murine prostate cancer cells (Figure W2) injected directly into the
tibial metaphysis of SPARC KO mice, we investigated the role of bone
stromal SPARC on the progression of bone-residing prostate cancer
and on bone lesion expansion. SPARC WT bones after RM1 injection
exhibited robust SPARC expression in the stromal cells, including
bone marrow and vasculature, with moderate expression by the RM1
cells and growth plate chondrocytes, whereas SPARC KO bones only
Figure 2. SPARC deficiency triggers enhanced bone resorption. RM1 (1 × 103) cells were injected into the tibia of SPARC WT (black
columns) or KO (white columns) mice. Sham PBS injections were performed on the contralateral leg. MicroCT was used to determine
bone morphometric changes in (A) BV/TV, (B) Tb.Th, (C) Tb.Sp, (D) Tb.N, and (E) BSA. Values were represented as mean percentage
change from initial ± SD measured for nine mice per group. *P < .05 by one-way ANOVA.
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displayed SPARC staining in the tumor with negligible stromal ex-
pression (Figure W3).
We recently characterized a model of intratibial RM1 injection as
a method to investigate prostate cancer: stromal interactions within
the bone of immune-competent syngeneic mice [17] and reported
that RM1 cells rapidly expand within bone secondary to a robust
osteolytic response. As expected, prostate cancer expansion proceeded
rapidly in the tibiae of both SPARC WT and KO mice resulting in
the displacement of bone marrow in the metaphysis (Figure 1A).
Prostate cancer growth in SPARC KO mice resulted in a loss of tra-
becular bone beneath the growth plate (Figure 1A). Whereas microCT-
derived individual transaxial slices within the secondary spongiosa of
SPARC WT and KO mice illustrated rapid osteolysis in both SPARC
WT and KO animals (Figure 1B), the lytic response in KO mice was
more robust and included a cortical breach (Figure 1B, arrow). Quanti-
fication of morphometric changes in a region distal to the metaphyseal
growth plate of injected tibiae indicated an approximately two-fold
greater reduction in trabecular bone volume (BV/TV) in SPARC KO
mice compared with WTmice (Figure 2A). Corresponding trends were
noted for Tb.Th and Tb.Sp, although the differences between SPARC
WT and KO were not significant (Figure 2, B and C ). The Tb.N in
SPARC KO mice was significantly lower than WT (Figure 2D), cor-
responding with our histologic data (Figure 1A). In concert with the
changes in BV/TV and Tb.N, the total BSA was lower in SPARC KO
mice compared with WT (Figure 2E). Thus, a loss of stromal SPARC
results in enhanced osteolysis on prostate cancer implantation. No sig-
nificant changes in the bone structure indices were seen between sham-
operated SPARC WT and KO mice (Figure 2). Moderately osteolytic
B16-F10 murine melanoma cells, when implanted into the tibia of
SPARC WT and KO mice, expanded but failed to promote extensive
osteolysis (Figure W4). Thus, this enhanced osteolysis in SPARC KO
mice is the result of bone-residing prostate cancer and not merely an
effect of tumor presence.
Osteoclast Numbers Are Increased in the Presence of RM1 Cells
Intratibial injection of RM1 cells stimulated osteolysis in SPARC
WT and KO mice. We used TRAP staining to visualize osteoclasts in
the presence and absence of RM1 cells and to assess their possible con-
tribution to the increased osteolysis (Figure 3, A–H ). The number of
TRAP-positive osteoclasts was equal or lower in SPARCKO bone com-
pared with WTafter sham injection (Figure 3, A, B, and I), confirming
other reports [19]. RM1 growth stimulated increased TRAP staining
in both SPARCWTand KOmice in the metaphysis below the epiphy-
seal growth plate (1.74- and 2.37-fold over sham, respectively; Figure 3,
C , D, and I). This effect was not seen in mice injected with B16-F10
melanoma cells (Figure W5). Interestingly, numbers of osteoclasts in
SPARC KO mice were 1.36-fold higher than in WTmice in the pres-
ence of RM1 cells (Figure 3,C ,D, and I ). In SPARC KOmice injected
with RM1 cells, a cortical breach occurred in an area of high osteoclast
numbers (Figure 3D, arrow). Osteoclast numbers were also seen to be
increased within a highly remodeling area of cortical bone in the di-
aphysis (Figure 3, E and F). Osteoclast numbers in SPARC KO mice
are particularly increased along the edges of the RM1 tumor and in the
secondary ossification center where remodeling continues to occur after
Figure 3. TRAP staining is increased in SPARC KOmice. A sham injectionwas performed as a control in SPARCWT (A) or KO (B and G)mice.
RM1 cells (1 × 103) were injected into the tibia of SPARC WT (C and E) or KO (D, F, and H) mice. Bones were isolated after 2 weeks of
intraosseous tumor growth and sectioned. Osteoclasts were visualized by TRAP staining (dark red) and counterstained with hematoxylin.
RM1 cells (T) can be seen growing in the proximal metaphysis and have completely replaced the bone marrow (BM). B indicates trabecu-
lar bone; GP, growth plate. Arrow indicates site of cortical breach (D). Scale bars, 50 μm (A–D); 200 μm (G and H). Representative im-
ages from nine mice are shown. (I) The number of TRAP-stained osteoclasts near the metaphysis of SPARC WT (black columns) or
KO (white columns) was counted and represented as mean osteoclast number ± SD (n = 7 bones from individual mice). *P < .05 and
***P < .001 by one-way ANOVA.
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loss of the trabeculae (Figure 3H ) compared with sham injection (Fig-
ure 3G ). Thus, bone-residing RM1 cells stimulate osteoclasts in
SPARC WT and KO mice.
RM1 Cell Growth Directly Stimulates
Osteoclast Differentiation
To determine whether RM1 growth directly affected osteoclast
differentiation, we cocultured RM1 cells with osteoclast progenitors
(BMMΦs) generated from SPARCWTand KO bone marrow by treat-
ment with M-CSF. Osteoclastic differentiation of BMMΦs was as-
sessed by TRAP staining and formation of TRAP-positive “osteoclast
like” multinucleated cells (MNCs; >3 nuclei; Figure 4A). Coculture
of BMMΦs with RM1 cells resulted in the formation of 4.2-fold higher
in SPARC WT and 7.8-fold higher in SPARC KO cultures compared
with BMMΦs cultured alone (Figure 4B). Interestingly, the numbers
of osteoclasts in SPARC KO cultures were 1.86-fold higher than WT
cultures in the presence of RM1 cells (Figure 4B). RM1 cells alone
demonstrated no TRAP staining, and BMMΦs alone formed less than
one MNC per field on average in the presence of M-CSF alone. Thus,
RM1 cell growth triggers increased osteoclast formation in both
SPARC WT and KO BMMΦ cultures, likely through the production
of RANKL. However, osteoclast progenitors in SPARC KO mice may
have enhanced differentiation or functional capabilities contributing to
the increased osteolysis after tumor challenge.
SPARC Inhibits Osteoclast Maturation and Bone Resorption
Our data derived from microCT and histologic analysis of prostate
cancer–induced bone lysis in vivo suggest that SPARC KO mice may
have an enhanced resorptive capacity on tumor challenge. To determine
whether osteoclast progenitor numbers are altered in SPARC KOmice,
bone marrow from SPARCWTand KO mice were cultured for 3 days
in the presence of M-CSF, and numbers of cells expressing the macro-
phage marker F4/80 were quantified. Treatment of SPARCKOmarrow
cultures with M-CSF resulted in a significant increase (1.48-fold) com-
pared with WT cultures, in the number of F4/80–expressing osteoclast
progenitor BMMΦ cells (Figure 5A), whereas the percentage of cells ex-
pressing F4/80 was similar (WT = 89.09% ± 4.38%, KO = 84.37% ±
8.15%). We next examined the osteoclastic differentiation of bone
marrow cells from SPARC WT and KO mice by TRAP staining and
formation of MNCs (Figure 5B). Treatment with M-CSF followed by
RANKL resulted in elevated numbers of TRAP-positive “osteoclast-
like” MNCs (>3 nuclei) per high-power field in marrow cultures of
SPARC KO mice (WT = 5.25 ± 1.42, KO = 6.75 ± 1.91). We next
examined osteoclast resorptive capacity using calcium phosphate–coated
slides. SPARC KO BMMΦ cells plated on calcium phosphate–coated
slides in the presence of M-CSF and RANKL displayed resorptive “pits”
of a greater total pit area and mean pit diameter (1.40- and 1.38-fold
greater, respectively) compared with WT (Figure 5C). These data in-
dicate that osteoclast progenitor sensitivity to M-CSF, a stimulator of
proliferation, is enhanced in marrow cultures of SPARC KO mice com-
pared with WTmice leading to a significant increase in the number of
F4/80–expressing cells and the formation of multinucleated osteoclast-
like TRAP-expressing cells possessing augmented resorptive capacity.
Enhanced Osteolysis Is Due to SPARC-null Osteoclasts,
Not Bone Structure
To determine whether the enhanced osteolysis in SPARC KO ani-
mals was due to increased osteoclast function or due to altered bone
structure, we plated SPARC KO and WT BMMΦs on parietal bones
from SPARC KO and WT mice. All cultures displayed large pits
(Figure 6A). SPARCKO cells resorbed 2.37-fold more bone on SPARC
KO and 2.74-fold more on WT bones compared with WT cells
(Figure 6B). The percent area resorbed by SPARC WT cells was simi-
lar on WT and KO bone (WT = 6.07% ± 1.48%, KO = 7.30% ±
1.67%). The altered bone structure due to the SPARC KO did result
in 1.39-fold higher resorption by SPARC KO cells compared with
the same cells on WT bone (Figure 6B). However, the deficiency of
SPARC in osteoclasts exerts a greater effect on osteolysis than the al-
tered bone architecture.
Discussion
We recently described a model to investigate prostate cancer: bone
stroma interactions in immune competent mice using the murine
RM1 prostate cancer cell line and direct intraosseous implantations
[17]. Herein, we use this model to elucidate the role of bone stromal
SPARC in metastatic prostate cancer progression and bone lesion ex-
pansion. Although there are several reports addressing the function of
SPARC in prostate cancer initiation and progression [4,10,11], it is un-
clear whether SPARC present in the bone tissue is involved in tumor-
induced lesion progression. The main conclusions from this study are
Figure 4. Prostate cancer growth induces osteoclast differentia-
tion. Osteoclast precursors (BMMΦ) were isolated from the bone
marrow of SPARCWT (black columns) or KO (white columns) mice.
Marrowwas flushed and plated in the presence of 100 ng/mlM-CSF.
Resulting BMMΦs and RM1 cells were plated alone or in coculture
then treated with 100 ng/ml M-CSF for 5 more days and stained for
TRAP. (A) Scale bars, 25 μm. (B) TRAP-positive BMMΦs and RM1
cells alone or in coculture were counted and displayed as mean ±
SD (n = 7 fields from duplicate experiments). ***P < .001 by one-
way ANOVA.
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the following: 1) quantitative microCT analysis of prostate cancer har-
boring SPARC KO bone reveals an enhanced tumor-induced osteolytic
response, 2) prostate cancer growth in the bone marrow cavity stimu-
lates osteoclast formation, which is increased in SPARC KO bones, 3)
SPARC KO marrow cultures exhibit increased expansion and aug-
mented formation of TRAP-positive MNC with heightened resorptive
capacity, and 4) enhanced osteolysis is due to increased resorption by
SPARC KO cells and not solely the altered bone structure. Together,
these results suggest that the presence of SPARC in host bone tissues,
and associated osteoclasts, limits the osteolysis and bone lesion progres-
sion stimulated by prostate cancer cells.
We have previously shown that RM1 cells induce an osteoclast-
mediated response in long bones of syngeneic mice leading to elevated
serum TRAP [17]. In addition, RM1 cells have the ability to enhance
proliferation of RAW264.7 monocyte-macrophage lineage cells [17]
and stimulate differentiation of osteoclast progenitors in vitro. The
model used previously [17] and in this study uses direct implantation
of RM1 cells within the marrow space of long bones. We demonstrate
that bone-residing RM1 cells stimulate osteoclast formation in vivo.
Similar to the data presented in our study, osteoclast numbers are in-
creased in patients with prostate cancer bone metastases [20]. In ad-
dition, it is apparent that the presence of an expanding bone-residing
tumor alone is not sufficient to enhance osteolysis as bone-residing
B16-F10murine melanoma cells did not result in an accentuated osteo-
clast response. This is supported by the fact that 80% of advanced
prostate cancers metastasize to bone compared with only 25% to
Figure 5. Osteoclast maturation is accelerated in SPARC KO mice. BMMΦs were isolated from the bone marrow of SPARC WT (black
columns) or KO (white columns) mice. (A) Marrow was flushed and plated in the presence of 100 ng/ml M-CSF. On the third day, cells were
fixed and stained for the macrophage marker F4/80 (green) to visualize BMMΦs. DAPI staining (blue) was used to show total cell numbers.
Scale bars, 50 μm. F4/80–positive cells were counted and displayed as mean ± SD (n = 7 fields from triplicate experiments). *P < .05 by
one-way ANOVA. (B) BMMΦ cells developed in vitro were then treated with 30 ng/ml M-CSF and 100 ng/ml RANKL for 3 more days. Scale
bars, 50 μm. Cells were stained for TRAP, counted, and displayed as mean ± SD (n = 12 fields from triplicate experiments). *P < .05 by
Student’s t test. (C) BMMΦ cells developed in vitro were plated, in the presence of 30 ng/ml M-CSF and 100 ng/ml RANKL, on calcium
phosphate–coated coverslips. Scale bars, 50 μm. Pit formation was quantified 3 days later with total pit area/field and mean pit diameter
was shown as mean ± SD (n = 20 fields from quadruplicate experiments). *P < .05 by Student’s t test.
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49% of advanced melanomas [21,22]. Thus, the RM1 prostate cancer
model is more proficient in producing an osteolytic response on im-
plantation into bone.
The RM1 model of prostate cancer bone metastasis has recently
been expanded on by Power et al. [23], wherein RM1 cells were con-
ditioned to home to bone after intracardiac injection. In addition,
intrafemoral injection of RM1 cells has been used to study bone me-
tastasis and its effects on bone marrow precursors [24]. These two stud-
ies open the possibility for the investigation of bone stromal SPARC as
a mediator of prostate cancer homing to bone in immune competent
mice. Previous studies have illustrated the potential of SPARC as a me-
diator of prostate cancer migration to bone extracts in vitro [8,12,13] or
the effects of tumor-expressed SPARC as a mediator of bone homing
potential [25], but no studies have investigated bone-resident SPARC
as a mediator of osteotropism in vivo. In light of studies indicating that
active bone remodeling promotes cancer homing to bone [26] and
that SPARC KO mice have impaired bone turnover [19], the use of
SPARC KO mice to investigate osteotropism of cancers may prove
fruitless as gradients of pro–bone-homing factors released from bone
during remodeling may be reduced or absent.
Bone remodeling is partially driven by osteoclasts, which are bone-
resorbing MNCs formed by the fusion of circulating or hematopoietic
tissue, such as bone, residing mononuclear precursors [27]. Differen-
tiation of osteoclasts is governed primarily by M-CSF, RANKL, and
levels of osteoprotegrin, a RANKL decoy receptor [28]. We have found
that marrow cells from SPARC KO mice have enhanced sensitivity
to M-CSF. In light of the larger mean pit size formed by SPARC KO
osteoclast-like cells compared with WT, it seems that SPARC restricts
osteoclast activity. Our findings that marrow cultures from SPARC
KO mice treated with M-CSF and RANKL lead to increased TRAP-
positive osteoclast-like cell formation is similar to those reported by
Machado do Reis et al. [29]. Despite this increase in osteoclast pre-
cursors in SPARC KO mice, there are fewer TRAP staining osteoclasts
in the bone of SPARC KO mice under basal conditions [19]. Our
data demonstrate that injection of RM1 cells into SPARC KO mice
stimulates increased osteoclast formation. In the sham-injected tibiae,
SPARC KO mice contain fewer osteoclasts compared with WT. This
may be a secondary effect due to decreased osteoblast numbers in
SPARC KO mice [19], resulting in lower RANKL levels and reduced
osteoclast differentiation. This decrease in differentiation may result in
an accumulation of osteoclast progenitors in SPARC KO animals [29].
On implantation of RM1 cells, which produce both transmembrane
and soluble RANKL, osteoclast differentiation is stimulated resulting
in increased numbers of osteoclasts and enhanced osteolysis. Prostate
cancers also produce cathepsin K, whose expression is increased on
metastasis to bone [30]. Cathepsin K was recently shown to cleave
SPARC in experimental bone metastases [15]. This cleavage of SPARC
could inactivate the protein, creating an environment similar to that of
the SPARC KO mouse, resulting in enhanced osteolysis and tumor
progression. In addition, we demonstrate that these stimulated SPARC
KO osteoclasts are more resorptive; further contributing to the in-
creased osteolysis.
Loss of stromal SPARC expression has been linked to enhanced
tumor growth in several cancer types [31–33] including prostate [11].
Each of these studies indicated that loss of SPARC expression resulted
in reduced quantities of tumor-associated collagen type I. Because col-
lagen type I is a major component of bone and its maturity [34,35]
seems to be altered in SPARC KO bone, it is possible that collagen type
I may play a role in the enhanced osteolytic response noted in SPARC
KO mice in the presence of bone-residing prostate cancer. Our data
demonstrate that whereas SPARC WT and KO osteoclasts formed in
culture display increased resorption on SPARC KO bones, SPARC
KO osteoclasts have increased resorptive activity on SPARC WT and
KO bones. Thus, whereas the altered structure of SPARC KO bone
due to collagen type I deposition plays a role in enhanced osteolysis,
the deficiency of SPARC in osteoclasts plays a greater role.
Our data illustrate a role for SPARC in the progression of bone me-
tastatic prostate cancer where bone stromal SPARC suppresses tumor
expansion by limiting osteoclast maturation and function. Lack of bone
stromal SPARC is associated with an apparent accentuated osteoclastic
response in bones challenged by prostate cancer and illustrates the
importance of SPARC not only in the maintenance of normal bone
mass and quality [19] but also in the regulation of bone remodeling
owing to pathological conditions such as bone metastatic prostate can-
cer. Because osteolysis is a key component of prostate cancer progres-
sion in bone and defines the course of both osteoblastic and osteolytic
Figure 6. SPARC KO osteoclasts are hyperresorptive. BMMΦs were
isolated from the bone marrow of SPARC WT (WT cells, black col-
umns) or KO (KO cells, white columns) mice. Marrow was flushed
and plated in the presence of 100 ng/ml M-CSF. After 3 days, 5 ×
105 BMMΦ cells were then placed on parietal bones from either
SPARC WT (WT bone) or KO (KO bone) mice and treated with
30 ng/ml M-CSF and 100 ng/ml RANKL for 5 more days. (A) Pits
formed by osteoclasts were visualized microscopically. Scale bars,
50 μm. Representative images from 10 fields are shown. (B) Pit
area was measured and represented as mean percentage area
resorbed ± SD (n = 10 fields from duplicate experiments). **P <
.01 and ***P < .001 by one-way ANOVA.
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bone lesions, these findings represent an important step in the develop-
ment of new approaches to treat bone metastases.
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Figure W1. SPARC KO tibia display decreased trabecular morphometric parameters. (A–E) MicroCT was used to determine the bone
morphometric parameters of SPARC WT (black columns) and KO (white columns) mice: (A) BV/TV, (B) Tb.Th, (C) Tb.Sp, (D) Tb.N, and
(E) BSA. Values were represented as mean ± SD measured for nine mice. *P < .05 by Student’s t test. (F) Whole bone extracts from
femurs of SPARC WT and KO mice lysed with RIPA buffer and separated by SDS-PAGE (4%-12%). (Left) Ponceau S (Sigma)–stained
nitrocellulose and (right) immunoblot analysis for SPARC (R&D Systems).
Figure W2. RM1 cells express and secrete SPARC and RANKL.
RM1 culture lysates and conditioned medium (CM) were collected.
Proteinswere separated by SDS-PAGE (10%) followed by (A) SPARC
and (B) RANKL (Santa Cruz Biotechnology) immunoblot analysis.
Both total (SPARC) or transmembrane (RANKL) (arrow) and soluble
(arrowhead) forms of the proteins were found.
Figure W3. RM1 cells produce SPARC in vivo. RM1 cells (1× 103) were injected into the tibia of SPARCWTor KO. Boneswere isolated after
2 weeks of intraosseous tumor growth and paraffin-embedded bone sections were stained for SPARC (green) using a method modified
from Trombetta and Bradshaw (J HistochemCytochem 2010;58:871–879). In brief, sections were deparaffinized, rehydrated, and blocked in
2% donkey serum/0.2% Triton X-100/PBS. Slides were incubated for 1 hour with SPARC antibody (R&D Systems) followed by incubation
with an antigoat secondary antibody conjugated to Alexa 488 (Molecular Probes). Coverslips were mounted with Vectashield (Vector Labo-
ratories, Burlingame, CA). Images were taken with a Leica DM2500 light microscope. Scale bars, 50 μm. Representative images from nine
mice are shown.
Figure W4.Melanoma implantation does not promote osteolysis. B16-F10 murine melanoma cells (1 × 104) were injected into the tibiae of
SPARC WT and KO mice. (A) Bones were isolated after 2 weeks of intraosseous tumor growth, sectioned, and stained with H&E. B16-F10
cells can be seen growing within proximal metaphysis. Scale bars, 50 μm. (B) MicroCT-derived proximal metaphyseal transaxial slices of the
tibiae both 1 day (initial) and 2 weeks (final) after B16-F10 cell implantation. Representative images from nine mice are shown.
Figure W5. Melanoma implantation does not stimulate osteoclast differentiation. B16-F10 cells (1 × 104) were injected into the tibia of
SPARC WT or KO mice. Bones were isolated after 2 weeks of intraosseous tumor growth and sectioned. Osteoclasts were visualized by
TRAP staining (dark red) and counterstained with hematoxylin. Scale bars, 50 μm. Representative images from nine mice are shown.
